E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

gear headHow cool is this? Shampoo for men in a quart of oil bottle!

Click the banner to get some now and tell the little lady to throw that other stuff in the trash!
TEVAPHARMIND SP ADR  
TEVAPHARMIND SP ADR
TEVALast: $50.39 ($+0.805)Volume: 4,872,632Last Trade: 8/5/2010 5:20:02 PM
Today

Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
 Options
Quote |  Alerts | | Free Newsletter
 
 Detailed Quote
NASDAQ:TEVA $50.39 ($+0.805 +1.6234%)
Industry: Health Sector: Pharmaceuticals
Open: 49.80 Previous Close: 49.585
Day's High: 50.65 Day's Low: 49.65
52-Week High: 50.00 52-Week Low: 35.39
 
Bid: 50.43 / 2,000 Ask: 50.44 / 1,000
Volume: 4,872,632 Outstanding: 764,000,000
Market Cap: $36 B
TEVAPHARMIND SP ADR Profile
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, produces and markets generic drugs covering all major treatment categories. Co.'s principal products are Copaxone for multiple sclerosis and Azilect for Parkinson's disease, as well as a proprietary specialty business, which consists primarily of respiratory products. Co.'s active pharmaceutical ingredient business sells to third-party manufacturers and provides vertical integration to its pharmaceutical production. Co.'s operations are conducted throughout North America, Europe, Latin America, Asia and Israel.
 TEVAPHARMIND SP ADR News & Press Releases

Teva Announces Agreement with Competition Bureau of Canada Regarding Proposed Merger with Ratiopharm
Teva Pharmaceutical Industries Ltd. ( TEVA ) today announced that the Competition Bureau in Canada has reached an agreement with Teva Canada Limited and the Me... [more]

Teva Reports Strong Second Quarter 2010 Results Driven by Growth in All Businesses
Teva Pharmaceutical Industries Ltd. ( TEVA ) today reported results for the quarter ended June 30, 2010. Second Quarter Highlights : <u... [more]

Teva Provides Update on Generic Protonix® Litigation
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that the U.S. District Court for the District of New Jersey denied Teva’s motion to overturn an Ap... [more]

Teva Announces Approval of Generic Effexor XR®
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today U.S. Food and Drug Administration (FDA) approval of Venlafaxine HCl ER Capsules, the Company’s gen... [more]

Teva Announces Pricing of $2.5 Billion of Senior Notes
Teva Pharmaceutical Industries Limited ( TEVA ) (“Teva”) announced today that it successfully priced the offering, by its special purpose finance subsidiaries,... [more]

Teva to Present at the UBS Global Specialty Pharmaceuticals Conference
Teva Pharmaceutical Industries Ltd. ( TEVA ) will host a live audio webcast at the UBS Global Specialty Pharmaceuticals Conference with Eyal Desheh, Teva's Chi... [more]

Teva Reaches Settlement Agreement With AstraZeneca Regarding Generic Entocort® EC Capsules
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that it has entered into an agreement with AstraZeneca to settle patent litigation regarding Teva'... [more]

Teva Provides Update on Las Vegas Trial
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that a Las Vegas Jury awarded $356M in punitive damages against Teva Parenteral Medicines. </p... [more]

Teva Reports First Quarter 2010 Results
Teva Pharmaceutical Industries Ltd. ( TEVA ) today reported results for the quarter ended March 31, 2010. First Quarter Highlights : <u... [more]

Teva Provides Update on Generic Protonix® Litigation
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that a jury returned a verdict in the U.S. District Court for the District of New Jersey finding t... [more]

Teva Settles Generic Eloxatin Litigation
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that patent infringement litigation pertaining to Teva's generic version of sanofi-aventis and Deb... [more]

Chartpoppers.com releases Investment overview on Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA)
( CHARTPOPPERS.COM , February 16, 2010 ) Point Roberts, WA - Chartpoppers.com announces an investment report featuring company Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) The Consolidated Investment Analysis on Teva Pharmaceut... [more]

Teva Reports Record Full Year 2009 and Fourth Quarter Results
Teva Pharmaceutical Industries Ltd. ( TEVA ) today reported record results for the quarter and year ended December 31, 2009. Full Year and Fourth Qua... [more]

Teva Announces Agreement on Famvir® Patent Challenge
Teva Pharmaceutical Industries Ltd. ( TEVA ) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with Novartis to sett... [more]

Court of Appeals Affirms Favorable Decision Regarding Generic Prevacid® SoluTab
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a Nov. 10, 2009, District Cour... [more]

European Medicines Agency (EMA) Waives Requirement to Test StemEx(R) in Paediatric Patients 17 Years
JERUSALEM, Israel , January 18 /PRNewswire/ -- - The International Study of StemEx, an Experimental Treatment for Leukemia, Lymphoma and MDS, is now Enrolling at Clinical Sites in Italy , Hungary... [more]

Teva Presents Strategic Plan to Deliver Strong Growth
During its investor meeting today, Teva Pharmaceutical Industries Ltd. ( TEVA ) presented an updated strategy, highlighting key opportunities for growth and an... [more]

Teva Announces Settlement Agreements with AstraZeneca Regarding Generic Prilosec® and Nexium®
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that it has entered into two definitive agreements with AstraZeneca to settle patent litigation re... [more]

Teva-KOWA Pharma to Acquire a Majority Share Interest in Taisho Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that Teva-KOWA Pharma Co., Ltd., the Company's joint venture in Japan with KOWA Company, Ltd., has... [more]

Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Manage
HORSHAM, Pa., Dec. 7 /PRNewswire-FirstCall/ -- Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd. ( TEVA ), today announced the publication of four articles in a special supplement of th... [more]

Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of Three COPAXONE®-Relat
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today it is seeking to amend its existing complaint against Momenta Pharmaceuticals, Inc./Sandoz Inc. to... [more]

Teva Reports Third Quarter 2009 Results
Teva Pharmaceutical Industries Ltd. ( TEVA ) today reported results for the quarter ended September 30, 2009. Third Quarter Highlights : </... [more]

Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for
JERUSALEM, ISRAEL -- (Marketwire) -- 10/19/09 -- Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.... [more]

Teva Comments on Mylan Paragraph IV Filing for COPAXONE®; Files Lawsuit against Generic Filer for Pa
Teva Pharmaceutical Industries Ltd. ( TEVA ) commented today on the abbreviated new drug application (ANDA) containing a Paragraph IV certification for COPAXON... [more]

Teva Provides Update on Generic Seroquel® Litigation
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a July 1, 2008 decision by the... [more]

Results of ADAGIO Study with AZILECT® in Parkinson’s Disease Published in New England Journal of Med
Results from the ADAGIO trial, published online today in The New England Journal of Medicine , demonstrated that Parkinson’s disease patients receiving AZIL... [more]

Teva Reports First Quarter 2009 Results
Teva Pharmaceutical Industries Ltd. ( TEVA ) today reported results for the quarter ended March 31, 2009. First Quarter Highlights : <u... [more]

New Data Illustrate Novel Mechanism OF Action of Laquinimod, an Oral Compound for the Treatment of M
JERUSALEM and LUND, SWEDEN and SEATTLE, WA -- (Marketwire) -- 04/29/09 -- Teva Pharmaceutical Industries Ltd. ( TEVA ) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from several new clinical and preclinical studies providing... [more]

Teva Announces Approval and Launch of Generic Topamax® Tablets
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that the U.S. Food and Drug Administration has granted approval for the Company’s Abbreviated New... [more]

Teva Announces FDA Response to Citizen Petition
Teva Pharmaceutical Industries Ltd. ( TEVA ) today announced that the Food and Drug Administration (FDA or “Agency”) has responded to their Citizen Petition (C... [more]

Teva Reports Record Full Year 2008 and Fourth Quarter Results
Teva Pharmaceutical Industries Ltd. ( TEVA ) today reported results for the quarter and full year ended December 31, 2008. Full Year and Fourth Quart... [more]

Teva and Lonza Announce Strategic Partnership to Become a Leading Global Provider of Biosimilars
Teva Pharmaceutical Industries Ltd. ( TEVA ) and Lonza Group Ltd. (SIX: LONN) today announced their agreement to establish a joint venture to develop, manufact... [more]

Teva Announces Tentative Approval of Generic Seroquel® Tablets
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company’s Abbrev... [more]

Teva Provides Update on Generic Pulmicort Respules® Launch
Teva Pharmaceutical Industries Ltd. ( TEVA ) announces that further to its press release dated November 19, 2008, the United States District Court for the Dist... [more]

Teva Announces Agreement on Allegra® Patent Challenge
Teva Pharmaceutical Industries Ltd. ( TEVA ) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., and Barr Laboratories, Inc. have signed an ag... [more]

Teva Completes Enrollment in Laquinimod Phase III Clinical Trial
LUND, SWEDEN -- (Marketwire) -- 11/18/08 -- - Recruitment Still Ongoing For Second, Pivotal Phase III Study, Bravo - Jerusalem, Israel and Lund, Sweden, November 18, 2008 - Teva Pharmaceutical Industries Ltd. ( TEVA ) and Active... [more]

Teva Reports Third Quarter 2008 Results
Teva Pharmaceutical Industries Ltd. ( TEVA ) today reported results for the quarter ended September 30, 2008. Third Quarter Highlights : </... [more]

Teva Announces Settlement Agreement Regarding Auction Rate Securities
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that it has entered into a settlement agreement with an institution that acted as a broker in plac... [more]

Teva to Report Third Quarter 2008 Financial Results on November 6, 2008
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that it will release its third quarter 2008 financial results on Thursday, November 6, 2008. <... [more]

Teva Announces Sale of Its Israeli Veterinary Business to Phibro Animal Health
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that it has entered into a definitive agreement to sell its Israeli based veterinary business unit... [more]

Teva and Kowa Announce Strategic Partnership to Create a Leading Generic Pharmaceutical Company in J
Teva Pharmaceutical Industries Ltd. ( TEVA ) and Kowa Company, Ltd. today announced that they have signed a definitive agreement to establish a leading generic... [more]

COPAXONE(R) Demonstrated Protective Effect in Patients with Clinically Isolated Syndrome Suggestive
New data from PreCISe, in clinically isolated syndrome patients, have demonstrated that COPAXONE ® (glatiramer... [more]

Teva Announces Appellate Court Reverses Generic Risperdal(R) Exclusivity Decision
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that following a hearing on September 12, 2008, the U.S. Court of Appeals for the District of Colu... [more]

Teva Reports Second Quarter 2008 Results
Teva Pharmaceutical Industries Ltd. ( TEVA ) today reported results for the quarter ended June 30, 2008. Second Quarter Highlights : <u... [more]

ADAGIO Phase III Top Line Data to be Presented at 12th Congress of European Federation of Neurologic
Teva Pharmaceutical Industries Ltd. ( TEVA ) today announced that results from the ADAGIO study will be presented at the 12 th Congre... [more]

Teva to Report Second Quarter 2008 Financial Results on July 29, 2008
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today that it will release its second quarter 2008 financial results on Tuesday, July 29, 2008. ... [more]

Teva Provides Update on FORTE Trial
Teva Pharmaceutical Industries Ltd. ( TEVA ) today announced top-line results from a Phase III study designed to assess the efficacy, safety and tolerability o... [more]

Teva to Present at the Piper Jaffray Third Annual Europe Conference
Teva Pharmaceutical Industries Ltd. ( TEVA ) will host a live audio webcast at the Piper Jaffray Third Annual Europe Conference in London. Dan Suesskind... [more]

Teva's AZILECT(R) 1 mg Tablets Meet End Points in ADAGIO Phase III Trial
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today the successful completion of ADAGIO, the phase III study designed to demonstrate that AZILECT<span... [more]

Teva to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
Teva Pharmaceutical Industries Ltd. ( TEVA ) will host a live audio webcast at the Goldman Sachs 29 th Annual Global Healthcare Confer... [more]

Teva to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
Teva Pharmaceutical Industries Ltd. ( TEVA ) will host a live audio webcast at the UBS Global Specialty and Generic Pharmaceuticals Conference in London. Dan S... [more]

Teva Reports First Quarter 2008 Results
Teva Pharmaceutical Industries Ltd. ( TEVA ) today reported results for the quarter ended March 31, 2008. First Quarter Highlights: -- Net sales of $2,572 million, up 24 percent compared to the first quarter of 2007. ... [more]

Teva Announces Global In-Market First Quarter Sales of Copaxone(R) Increased 35% to $542 Million
Teva Pharmaceutical Industries Ltd. ( TEVA ) announced today, in conjunction with the release of the Sanofi-aventis group's financial results, that global in-m... [more]

Abbott and Takeda's Partnership TAPed Out
Motley Fool:  - Mar 20, 2008 ... since rival Wyeth's (NYSE: WYE) Protonix is now available as a generic from Teva Pharmaceutical ( Nasdaq: TEVA ) and as a licensed generic from Wyeth. ...

Teva spends big on US lobbyist activities
Globes: , Israel - 13 hours ago A US government document shows that Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA) spent $2.3 million on lobbyist activities in Washington ...

Teva to Present at the Lehman Brothers 11th Annual Global ...
PR-Inside.com (Pressemitteilung): Teva to Present at the Lehman Brothers 11th Annual Global ... , Austria - Mar 18, 2008 Teva Pharmaceutical Industries Ltd. ( Nasdaq:TEVA ) will host a live audio webcast at the Lehman Brothers 11th Annual Global Healthcare Conference i

S&P raises Teva credit rating
Globes: , Israel - Mar 18, 2008 ... credit and senior unsecured debt ratings on Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA) to 'BBB+ with a stable outlook from 'BBB'. ...

Citi downgrades Teva: The bank called a Teva take-over of Mylan "a ...
Trading Markets (press release): Citi downgrades Teva: The bank called a Teva take-over of Mylan "a ... , CA - Mar 18, 2008 ... Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA | news | PowerRating | PR Charts ) to "Hold" from "Buy" and cut its

BioSante Pharmaceuticals Reports Product Development Highlights ...
Nanotechnology News (press release): BioSante Pharmaceuticals Reports Product Development Highlights ...  - Mar 17, 2008 In June 2007, BioSante and a subsidiary of Teva Pharmaceutical Industries Ltd. ( NASDAQ: TEVA ) signed an amendment to its development and license agreement

Teva raised to 'BBB+' on expected solid opg performance, leading ..
CNNMoney.com: Teva raised to 'BBB+' on expected solid opg performance, leading ...  - Mar 17, 2008 ... Industries Ltd ( NASDAQ:TEVA ) to 'BBB+' with a stable outlook from 'BBB' to reflect its leading position in the growing gene

(Nanowerk News) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX ...
Nanowerk LLC: (Nanowerk News) BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX ... , HI - Mar 17, 2008 In June 2007, BioSante and a subsidiary of Teva Pharmaceutical Industries Ltd. ( NASDAQ: TEVA ) signed an amendment to its development and license agr

Teva Pharmaceutical Has Strong Quarter: Fool by Numbers
Motley Fool:  - 5 hours ago On May 2, Teva Pharmaceutical ( Nasdaq: TEVA ) released first-quarter earnings for the period ended March 31. Quarterly revenues grew by 24.3% due to strong ...

Tue: Real estate boosts TASE
Globes: The investment bank recommends the following Israeli shares under this scenario: Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA), banks, ...

It's a Wide World
Motley Fool:  - 8 hours ago Top holdings include Samsung Electronics at 6%, Taiwan Semiconductor (NYSE: TSM) at 2%, and Teva Pharmaceutical ( Nasdaq: TEVA ) at 1.8%. ...

LifeWave fails to explain share price surge, and plummets 20%
Globes: , Israel - 1 hour ago ... except for dual-listed Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA) and Perrigo Company (Nasdaq:PRGO; TASE:PRGO). ...

TEVA (TEVA) Said Higher Dose COPAXONE Increased Efficacy in ...
StreetInsider.com (subscription): TEVA (TEVA) Said Higher Dose COPAXONE Increased Efficacy in ... , MI - 1 hour ago Teva Pharmaceutical Industries Ltd ( NASDAQ: TEVA ) sai da 9-month, randomized, double-blind, parallel-group Phase II study of 90 patients comparing a 40

Data Published in Neurology Showed That Higher Dose of COPAXONE(R ...
Genetic Engineering News (press release): Data Published in Neurology Showed That Higher Dose of COPAXONE(R ... , NY - 2 hours ago In North America, COPAXONE(R) is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd. ( NASDAQ:TEVA )

Data Published in Neurology Showed That Higher Dose of COPAXONE ...
Business Wire (press release): Data Published in Neurology Showed That Higher Dose of COPAXONE ... , CA - 2 hours ago In North America, COPAXONE ® is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd. ( NASDAQ:TEVA ).

Mylan Laboratories: Making the good (generic) drugs
Blogging Stocks: Competitors include Teva Pharmaceutical Industries ( NASDAQ: TEVA ) and Watson Pharmaceuticals (NYSE: WPI). The stock is up over the past month, ...

Thu: Protalix-still a biotech dream
Thu: Protalix - still a biotech dream - Globes: Thu: Protalix - still a biotech dream Globes, Israel - 2 hours ago Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA) has placed substantial focus on this area and among other things, it has already forged a ...

Teva to recruit 200 for new Jerusalem plant
Globes: Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA) announced today that it will hire 200 employees this year for its new plant in Har Hotzvim ...

Teva to recruit 200 for new Jerusalem plant
Globes: Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA) announced today that it will hire 200 employees this year for its new plant in Har Hotzvim ...

Foreign Capital Finds Fertile Ground
Forbes: , NY - 18 hours ago Already, Teva Pharmaceutical Industries ( nasdaq: TEVA - news - people ) and Check Point Software Technologies (nasdaq: CHKP - news - people ) ...

Foreign Capital Finds Fertile Ground
Forbes: , NY - 18 hours ago Already, Teva Pharmaceutical Industries ( nasdaq: TEVA - news - people ) and Check Point Software Technologies (nasdaq: CHKP - news - people ) ...

Clal Biotechnologies TASE IPO set at $250m value
Globes: , Israel - 5 hours ago Ltd. (TASE:IDBH) subsidiary Clal Industries and Investments Ltd. (TASE: CII) owns 81% of CBI and Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; ...

Shlomo Nehama mooted as Hirchson replacement
Globes: , Israel - 23 hours ago Next is Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA) chairman Eli Hurvitz with 21%, followed by former Minister of Justice and Finance ...

Drug co Se-cure signs contracts worth at least €39m
Globes: , Israel - Mar 25, 2007 The sources also added that the company has signed a distribution agreement with Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA) for the ...

Teva one of 2 finalists in Merck KGaA tender-report
Teva one of 2 finalists in Merck KGaA tender - report - Globes: Teva one of 2 finalists in Merck KGaA tender - report Globes, Israel - Mar 25, 2007 India’s “The Economic Times” reports that Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA) may be one of the two finalists in the tender

Cephalon Subpoenaed Over Provigil Deals
Forbes: , NY - Mar 23, 2007 Settlements were made with Barr Laboratories Inc. (nyse: BRL - news - people ), Teva Pharmaceutical Industries Ltd. ( nasdaq: TEVA - news - people ), Ranbaxy ...

Analyst initiations 3-23-07: CVS Corp, JC Penney, Federated Dept ...
Blogging Stocks: Analyst initiations 3-23-07: CVS Corp, JC Penney, Federated Dept ...  - Mar 23, 2007 UBS initiated Teva Pharmaceutical Industries Ltd ( NASDAQ: TEVA ) with a Buy rating. Pacific Growth started American Superconductor Corp (NASDAQ: AMSC) wit

Teva: Making a Foray into Biogenerics?
Seeking Alpha: , NY - 22 hours ago Not the one with which we are all familiar from the activity of Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ), but the generic biotechnology sector ...

Makhteshim seeks new direction
Globes: , Israel - 13 hours ago ... a plan shaped by former CEO Shlomo Yanai, who was recently appointed CEO of drugs giant Teva Pharmaceutical Industries Ltd. ( Nasdaq: TEVA ; TASE: TEVA). ...

Vaccinex Announces Antibody Development and Commercialization ...
Drug Newswire (press release): Vaccinex, Inc. announced today that it has entered into a collaboration with Teva Pharmaceutical Industries Ltd. ( NASDAQ:TEVA ) to develop ...


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright © 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts